| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.09. | NSE - Abpro Holdings, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | - | SEC Filings | ||
| ABPRO Aktie jetzt für 0€ handeln | |||||
| 25.08. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.06. | Abpro Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | Abpro Holdings, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | Abpro Holdings, Inc. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 10.02. | Morning Market Movers: Abpro, Tectonic Therapeutic, Upwork, Ichor Holdings See Big Swings | 803 | AFX News | AKRON (dpa-AFX) - At 6:30 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 15.12.25 | Abpro Holdings Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T cell engager ABP-102/CT-P72 for HER2-positive Cancers | 534 | GlobeNewswire (Europe) | IND submitted for ABP-102/CT-P72, a HER2 × CD3 T cell engager, with preclinical studies demonstrating enhanced HER2-high tumor selectivity and a favorable safety profile ABP-102/CT-P72 represents Abpro's... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,205 | -0,14 % | Ihre wichtigsten Termine: Spannende Updates von: Moderna, Krones, Daimler Truck, Under Armour & Brookfield | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag Enthaltene Werte: CA29250N1050... ► Artikel lesen | |
| CG ONCOLOGY | 75,93 | +17,18 % | Kurssprung bei CG Oncology: Starke Quartalszahlen und Pipeline-Katalysatoren treiben die Aktie an | ||
| COGENT BIOSCIENCES | 31,645 | +6,98 % | Cogent Biosciences, Inc. - 8-K, Current Report | ||
| EDGEWISE THERAPEUTICS | 45,030 | +15,79 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| MODERNA | 227,50 | +5,72 % | PRESSESPIEGEL/Unternehmen: AUDI, BMW/MERCEDES, VW, MODERNA/MERCK & CO, OMV, NVIDIA, TANDEM HEALTH, COMMERZBANK/UNICREDIT | DJ PRESSESPIEGEL/Unternehmen
Die wirtschaftsrelevanten Themen aus den Medien, zusammengestellt von Dow Jones Newswires.
AUDI - Der umstrittene Auftritt des Audi-Chefs Gernot Döllner an der... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,070 | +4,09 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| KINIKSA PHARMACEUTICALS | 93,86 | +6,25 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| NURIX THERAPEUTICS | 15,300 | +3,10 % | Morning Market Movers: Curis, Inc., Darkiris, Amdocs, Nurix Therapeutics See Big Swings | NICOSIA (dpa-AFX) - At 8:05 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,350 | +15,22 % | Stifel cuts Summit Therapeutics stock price target on valuation | ||
| ARCUTIS BIOTHERAPEUTICS | 25,545 | -5,39 % | Arcutis falls after Q3 earnings miss | ||
| IMMUNOVANT | 30,510 | +7,47 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| ADMA BIOLOGICS | 12,720 | -3,71 % | ADMA Biologics hits 10-month high as Asceniv drives Q3 beat | ||
| IMMUNOME | 18,710 | +4,50 % | Immunome, Inc.: Immunome Announces EMA Validation of Marketing Authorization Application for Varegacestat for the Treatment of Adults with Desmoid Tumors | The Marketing Authorization Application (MAA) is supported by positive Phase 3 RINGSIDE results demonstrating statistically significant improvements across the primary and all key secondary endpoints... ► Artikel lesen | |
| VERA THERAPEUTICS | 29,790 | -1,16 % | Guggenheim senkt Kursziel für Vera Therapeutics nach Modellanpassungen | ||
| KYMERA THERAPEUTICS | 131,71 | +2,80 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen |